APP, Second Chinese Heparin API Importer, Steps In To Fill Blood Thinner Need
This article was originally published in PharmAsia News
Executive Summary
APP Pharmaceutical, formerly Abrexis Pharmaceutical Products, is positioning itself to be a major supplier of blood thinner to hospitals and kidney-dialysis centers. The Illinois-based firm also imports some of its active ingredient from an unnamed supplier in China, but unlike the supplier of Baxter International's troubled heparin, the APP supplier in China has been inspected by the U.S. FDA. The agency acknowledged it did not inspect Baxter's supplier because it confused the name of the company. The agency moved quickly to approve APP-related facilities to avoid a national shortage of the blood-thinner. APP says it is ready to supply U.S. needs for the drug by producing its generic version of heparin at two U.S. plants. (Click here for more - a subscription may be required